Galectin Therapeutic (GALT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 09-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 32,556 | 40,768 | 43,328 | 47,480 | 50,337 |
| TOTAL | $33,883 | $41,120 | $43,884 | $48,209 | $50,473 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 166 | 197 | 227 | 258 | 287 |
| TOTAL | $166 | $197 | $227 | $258 | $287 |
| Total Assets | $34,049 | $41,317 | $44,111 | $48,467 | $50,760 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 691 | 206 | 660 | 1,661 | 354 |
| Accrued Expenses | 1,797 | 4,003 | 656 | 1,093 | 862 |
| TOTAL | $2,488 | $4,275 | $1,316 | $2,820 | $1,216 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 19 | 31 | 42 | 52 | 62 |
| TOTAL | $19 | $31 | $42 | $52 | $62 |
| Total Liabilities | $2,507 | $4,306 | $1,358 | $2,872 | $1,278 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 57,077 | 57,044 | 57,029 | 57,031 | 56,886 |
| Common Shares | 56 | 56 | 56 | 56 | 56 |
| Retained earnings | -232,080 | -226,125 | -219,945 | -216,394 | -211,191 |
| Other shareholders' equity | 2,250 | 2,260 | 2,260 | 2,260 | 2,260 |
| TOTAL | $31,542 | $37,011 | $42,753 | $45,595 | $49,482 |
| Total Liabilities And Equity | $34,049 | $41,317 | $44,111 | $48,467 | $50,760 |